Researchers at Lund University have unexpectedly discovered that an old cancer drug can be used to prevent rejection of transplanted tissue.
The researchers now have high hopes that their discovery could lead to new treatments for both transplant patients and patients with autoimmune diseases.
The researchers behind the study, which has been published in the scientific journal PLOS ONE, work at the Rausing Laboratory, Lund University, where they have conducted research on brain tumours over many years.
“Our group were studying the effects of the old tumour drug Zebularine, developed in the USA in the 1960s, and by chance we discovered that it had completely unexpected effects on the immune system”, says Leif Salford, Senior Professor of Neurosurgery.
“It turned out that Zebularine has the ability to subdue the reaction of the body’s immune system. This could be important in situations where tissue or organs are transplanted. We also think it could be used to curb the body’s attacks on its own tissue in autoimmune diseases, for instance type 1 diabetes or rheumatoid arthritis”, says Dr Nittby.
In studies on animals, the researchers used rats that were made diabetic. The researchers transplanted the islets of Langerhans – cell groups in the pancreas producing insulin – from healthy rats from another kind of rat into those with diabetes. The diabetic rats were divided into two groups; one group were treated with Zebularine and the other, the control group, did not receive any treatment. The diabetic rats that were treated with Zebularine survived for a significantly longer period than the untreated rats.
“It is very interesting that we only treated them with Zebularine for two weeks, but the effects of the treatment could be observed throughout the 90-day follow-up period.
“The findings are very exciting and are a sign that the immune system was not just generally suppressed, but that the treatment was more targeted. Neither did we see any signs of side-effects”, said Dr Nittby.
The researchers are now working intensively to further refine the treatment. The next step is to teach certain cells in the immune system – the dendritic cells – to accept certain specific proteins using the Zebularine treatment.
This would mean that the treatment could be targeted even more.
“If we succeed with that, we believe it could be of clinical significance both to prevent rejection of transplanted organs and to stop the body attacking its own tissue in autoimmune diseases.
The Latest Bing News on:
Zebularine
- Feed has no items.
The Latest Google Headlines on:
Zebularine
[google_news title=”” keyword=”Zebularine” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
The Latest Bing News on:
Preventing rejection of transplanted tissue
- Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for the Treatment of Familial Adenomatous Polyposis (FAP)on April 26, 2024 at 5:30 am
Biodexa Enters Into Exclusive License to eRapa™, a Phase 3 Ready Asset for theTreatment of Familial Adenomatous Polyposis (FAP) Worldwide rights come with $17 million in non-dilutive grant funding for ...
- NYU Langone surgeons perform first combined mechanical heart pump and gene-edited pig kidney transplant surgeryon April 25, 2024 at 12:19 pm
Surgeons at NYU Langone Health performed the first combined mechanical heart pump and gene-edited pig kidney transplant surgery.
- First combined heart pump, pig kidney transplant in same patient successfulon April 25, 2024 at 7:01 am
NYU Langone surgeons pave the way for xenotransplantation with a successful combined heart pump and gene-edited pig kidney transplant.
- 'We have combined two marvels of modern medicine': Woman gets pig kidney and heart pump in groundbreaking procedureson April 25, 2024 at 3:00 am
In a medical first, doctors transplanted a gene-edited pig kidney into a human patient after giving her a new heart pump.
- MIT Technology Reviewon April 24, 2024 at 11:00 am
Richard Slayman became the first living person to receive a kidney transplant from a gene-edited pig. Now, a team of researchers from NYU Langone Health reports that Lisa Pisano, a 54-year-old woman ...
- 14 recent scientific breakthroughson April 24, 2024 at 8:40 am
T cells are integral in the immune system but can become "dysfunctional inside tumors." "The approval of Amtagvi represents the culmination of scientific and clinical research efforts leading to a ...
- United Therapeutics Reports First Successful Xenothymokidney Transplanton April 24, 2024 at 6:18 am
By Chris Wack United Therapeutics reported the world's first successful transplant of a UThymoKidney, which the company produced, into a living person ...
- Woman becomes 1st patient to undergo combined heart pump implant and pig kidney transplanton April 24, 2024 at 6:01 am
In a first-of-its-kind procedure, a terminally ill patient has become the first person in the world to undergo a gene-edited pig kidney transplant and also have a mechanical heart pump surgically ...
- First-Ever Combined Heart Pump and Pig Kidney Transplant Gives New Hope to Patient with Terminal Illnesson April 24, 2024 at 1:59 am
Doctors performed this feat in two stages: first surgically implanting the heart pump days before embarking on the landmark transplant, which included a gene-edited pig kidney and the pig's thymus ...
- Study finds promising biomarker for cellular rejection after organ transplanton April 18, 2024 at 7:19 am
Today, patients who receive an organ transplant need repeated surgical biopsies to test for acute cellular rejection (ACR) throughout their lifetimes. But a blood test for ACR could be on the horizon ...
The Latest Google Headlines on:
Preventing rejection of transplanted tissue
[google_news title=”” keyword=”preventing rejection of transplanted tissue” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
